Pimozid 2 – 4  (TABLETS)

Each tablet contains 2 or 4 mg Pimozide.

Pimozid is a member of the Diphenyl-Butyl-Piperidine group, structurally similar to haloperidol. It is thought to block CNS dopaminergic receptors. It has no effect on noradernaline receptors.

Pimozid is indicated for acute and chronic schizophrenia, mania and hypomania, as an adjunct to the short term management of moderate to severe psychomotor agitation and excitement.

Dosage should be individually determined under clinical supervision. Consideration should be given to the age of patient, severity of symptoms and previous response to other neuroleptic drugs. Elderly patients require half the normal starting dose. Pimozid is not intended for administration in children under 12 years of age.

  1. Schizophrenia: Initial dose 10mg daily. This may be gradually increased, if necessary, to a maximum of 20 mg daily.
  2. Prevention of relapse: Initial doses 2mg daily and maintenance dose is between 2-20 mg daily.
  3. Mania, hypomania, psychmotor agitation and excitement: initial dose 2- 4 mg daily. It may be gradually increased, if necessary, to a maximum of 10mg daily.
  4. Non psychotic emotional disturbances (such as anxiety, tension): 2- 4mg daily, maximum dose is 20mg daily.

Hypersensitivity to pimozide or other Diphenyl - Butyl - Piperidine derivatives. Pheochromocytoma or thyrotoxicosis. Epilepsy and conditions predisposing to epilepsy (e.g. alcohol withdrawal and brain damage). Patients with arrhythmia.

Extrapyramidal symptoms may occur such as tardive dyskinsia which is common among patients treated with moderate to high doses of antipsychotic drugs for prolonged periods of time and may prove irreversible, particularly in patients over 50 years of age. Dose related side effects: drowsiness, insomnia and anxiety. Gastrointestinal symptoms such as nausea, constipation or dyspepsia and dry mouth. Hormonal effects including hyperprolactinemia, may cause oligo or amenorrhoea gynaecomastia. Signs of autonomic dysfuntion such as tachycardia, labile arterial pressure and sweating may precede the onset of hyperthermia.

Pimozide may increase the central nervous system depression produced by other CNS depressant drugs, including alcohol, hypnotics, sedatives or opioid analgesics. Pimozide may diminish the anti-parkinson effect of Levadopa. The dosage of anticonvulsants may need to be increased to take into account the lowered seizure threshold. The possible additive effects of concomitant use of other drugs known to prolong the QT interval (other antipsychotic drugs, cardio-active drugs) should be considered in patients receiving long term pimozide treatment.


  1. Periodic assessment of cardiac function should be undertaken in those patients receiving pimozide in excess of 16 mg daily. If Prolongation of QT interval or T - Wave changes appear or arrythmias develop, the need for treatment with pimozide should be reviewed.
  2. Pimozide should be used with caution in patients with hepatic or renal dysfunction.
  3. Patients should be advised not to drive or operate machinery during treatment because of the risks of sedation.

It is not advisable to administer the drug in pregnancy. Breast feeding should be discontinued because the drug may be excreted in breast milk.

Carton pack contains 2 blisters  each of 10 tablets with concentration of 2 or 4mg, with leaflet.



© 2010 Domina Pharmaceuticals